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Abstract: Background: Alzheimer’s disease (AD) is a dementia, a neurodegenerative con-
dition, and a protein-misfolding disease or proteinopathy, characterized by protein deposits, 
extracellular plaques and intracellular neurofibrillary tangles, which contain the AD’s typi-
cal pathological proteins, abnormal -amyloid and hyperphosphorylated tau, respectively, 
and are located predominantly in the cortex of the frontal, parietal, and temporal brain 
lobes. What is the role of molecular chaperones in AD? Data indicate that molecular 
chaperones, also known as Hsp, are involved in AD, probably displaying protective roles 
and/or acting as pathogenic factors as it occurs in chaperonopathies in which case AD 
would be suitable to chaperonotherapy. Hsp60, Hsp70, and Hsp90 can be augmented and 
overexpressed or diminished and downregulated in various situations in AD affected tis-
sues and cells, indicating they are active during disease development and progression. 
Question: What is the role of molecular chaperones in AD? Data indicate that molecular 
chaperones, also known as Hsp, are involved in AD, probably displaying protective roles and/or acting as 
pathogenic factors as it occurs in chaperonopathies in which case AD would be suitable to chaperonotherapy. 
Objective: Investigate the role of Hsp in AD, focusing on Hsp60, Hsp70, and Hsp90. Method: Critical 
examination of published data. Results: Hsp60, Hsp70, and Hsp90 can be augmented and overexpressed or 
diminished and downregulated in various situations in AD affected tissues and cells, indicating they are active 
during disease development and progression. Conclusion and Perspectives: Notwithstanding that the roles and 
mechanisms of action of chaperones in AD are still incompletely understood, there is already enough evidence 
to encourage the development of therapeutic strategies targeting them, either to block their activity in case they 
promote disease progression or to boost their performance when they are protective. The latter is an example of 
positive chaperonotherapy, which also includes chaperone replacement via gene or protein administration. On 
the contrary, if a chaperone is found to help the disease, it has to be blocked or eliminated, which constitute 
modalities of negative chaperonotherapy. 
Keywords: Chaperonopathies, protein-misfolding diseases, Alzheimer’s disease, -amyloid, tau, molecular chaperones, chaperonotherapy. 
1. INTRODUCTION 
 Alzheimer’s disease (AD) is a form of dementia. The loss of 
mental power that includes, depending on clinical stage, loss of 
memory; diminished capacity to understand complex concepts and 
face daily problems and solve them rapidly; impaired ability for 
communication; poor judgment; disorientation; confusion; behav-
ioral changes and other psychological and motor abnormalities; is 
called dementia [1-3]. The causes of dementia are varied, for exam-
ple, stroke with ischemic encephalopathy (multi-infarct or vascular 
dementia); head trauma; hydrocephalus; encephalitis; lysosome 
storage disease; chronic alcoholism; demyelinative conditions such 
as multiple sclerosis; and neurodegenerative diseases such as AD, 
Parkinson’s and Huntington’s diseases, Lewy body dementia, and 
others. 
 AD is a neurodegenerative condition. Classification of neu-
rodegenerative diseases is still a project in progress and currently 
includes data from epidemiology, molecular biology, molecular 
genetics, and genetics [4-6]. However, the classification based on 
the predominant anatomic location of the distinctive pathological  
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proteins and lesions continues to be useful even today in practice, in 
clinics and clinical pathology. Consequently, one may speak of 
degenerative diseases affecting predominantly the gray matter, or 
the basal ganglia and nigrostriatal system, or the motor neurons, or 
the spinocerebellar system, among others [5, 7]. AD falls within the 
gray matter group, since the most affected structures are the cortex 
of the frontal, temporal, and parietal lobes; there is also some par-
ticipation of the hippocampus. 
 AD is nowadays considered a member of the protein misfolding 
diseases [8-10]. These pathologic conditions have protein deposits, 
i.e., protein aggregates-precipitates, as one of the distinctive charac-
teristics, and are considered proteinopathies. A protein is altered 
due to mutation or aberrant post-translational modification, namely 
it is a pathological form of a normal protein, and tends to form re-
versible aggregates and irreversible precipitates. These pathological 
molecules and the multimolecular deposits they form may be toxic 
to the cell, or may at least constitute a burden to the cell and inter-
fere with its normal physiology. These conditions may be consid-
ered primary proteinopathies and AD is one of them. 
 Secondary proteinopathies are due to failure of the chaperoning 
system, which leads to multimolecular deposits (reversible aggre-
gates and irreversible precipitates) of normal proteins and, even 
more so, of pathological proteins with tendency to aggregate. 
Whether this is the case for AD it is still unclear. Some data seem to 
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indicate that deficiencies in the chaperoning system, particularly in 
the protein-degradation arm with participation of the ubiquitin-
proteasome and chaperone-mediated autophagy machineries, may 
be involved in AD [11-13]. However, there is no definitive evi-
dence that a failure of the chaperoning system by itself contributes 
in a determinant fashion to the pathogenic mechanism of AD [14]. 
In any case, the information already available encourages the de-
velopment of chaperonotherapy for AD, as discussed later. 
 As a typical proteinopathy, AD is characterized by abnormal 
proteins with mutations or post-translational modifications that 
interfere with their normal functions and status (soluble or not) and 
metabolism inside the cell [15-17]. Mutant proteins are the amyloid 
precursor protein (APP) and presinilins 1 and 2 (PS1 and PS2). In 
addition, the pathological, post-translationally modified protein in 
AD is the microtubule associated protein tau, which is hyper-
phosphorylated. These alterations, mutation and post-translational 
modifications, make the pathological proteins prone to aggregate 
and precipitate and, thereby, form the extracellular neuritic plaques 
and the intracellular tangles. While in the plaques abnormal forms 
of APP (i.e., -amyloid produced by abnormal cleavage APP) pre-
dominate, in the tangles tau is the main component [18-20]. 
 The molecular composition of the plaques and tangles has been 
investigated since many years ago in attempts to gain insight into 
the mechanisms that lead to their formation [18-23]. These studies 
illustrate the real power of histopathology at various levels of reso-
lution (e.g., optical and electron microscopies), including comple-
mentary methods (immunohistochemistry and Western blotting, 
among others) to dissect complex histological bodies, plaques and 
tangles in the case of AD, into their molecular components. The 
results of this multipronged histopathological approach are summa-
rized in Table 1 [7, 13]. 
 Many but no all Hsp are chaperones and there are chaperones 
that are not Hsp. Nonetheless, the terms Hsp and chaperones are 
used indiscriminately in the literature and we will use them as 
synonyms in this article. It has been realized that the chaperones 
constitute a physiological system distributed throughout the body 
and its components are present in all cellular compartments as well 
as extracellularly [14]. In addition, many conditions have been 
identified in which one or more components of the chaperoning 
system are abnormal, quantitatively and/or qualitatively, and are at 
the basis of pathogenic mechanisms that lead to manifest cell and 
tissue pathology and disease. These diseases, in which abnormal 
chaperones play an etiologic-pathogenic role, are the chapero-
nopathies [24]. The question is: are Hsp-chaperones quantitatively 
(elevated or decreased) and/or qualitatively (e.g., post-
translationally modified, or mutated) abnormal in AD-affected cells 
and tissues, e.g., in plaques and tangles? Namely, are there signs 
indicating that AD is a chaperonopathy? Data in Table 1 show that 
Hsp-chaperones are present in the affected brain tissue, but their 
possible structural abnormalities (e.g., post-translational modifica-
tions) and their pathogenetic or protective roles in AD are still un-
der study. Clarification of this issue will have an impact on how AD 
is approached clinically and therapeutically. For example, it may be 
found that a given chaperone is a good indicator of disease status 
and, thus, this chaperone will become a biomarker worth measuring 
periodically in the patient’s follow up. If, in addition, it is estab-
lished that a given chaperone actively contributes to disease initia-
tion and/or progression one may think of ways to eliminate or block 
the pathogenic chaperone. Likewise, if a chaperone malfunction or 
functional failure is identified as cause of pathology, strategies and 
means to replace the defective chaperones will have to be devel-
oped. In other words, if AD is found to be a chaperonopathy, it will 
become clear that it is a condition amenable to chaperonotherapy, 
positive when chaperone replacement or boosting is to be imple-
mented, or negative, when the pathogenic chaperone is to be bloc-
ked or eliminated [25-27]. 
 Where to look for chaperones in AD and what to look for? 
Since we now know that chaperones can reside and function ex-
tracellularly as well as intracellularly, and that their quantity and 
distribution changes in many pathological processes, one of the first 
objectives would be to determine if there are quantitative variations 
of chaperones around and inside the various cell types in the af-
fected brain tissue, including plaques and tangles. On this, there is 
some information already, which will be discussed later. 
 What chaperones to look for in AD? There is a large variety of 
chaperones, and those that have been found to cause chapero-
nopathies are displayed in Table 2. Since mitochondria are affected 
in AD, to the point that for some authors AD is a mitochondriopa-
thy [28, 29], and considering that the mitochondria unfolded protein 
response (mtUPR) is activated in AD [30], chaperones known to 
reside and work in mitochondria should be preferentially targeted 
for analysis. In this regard, Hsp60 and Hsp10 are the pertinent can-
didates, and the information currently available about them is dis-
cussed later. 
 On the other hand, considering that AD is a proteinopathy, with 
accumulation of misfolded proteins, which are known to trigger the 
unfolded protein response (UPR) with major involvement of the 
endoplasmic reticulum (ER) [31], one may target for analysis those 
chaperones that work in the ER, for example GRP78/BiP, GRP94/ 
gp96, GRP170/ORP150, GRP58/ERp57, PDI, calnexin, cal-
reticulin, and the co-chaperone SIL1, just to name some candidates 
for study. The available information about some of them in what 
pertains to AD is discussed later. 
2. ALZHEIMER’S DISEASE, CELLULAR STRESS, AND 
CHAPERONES 
 AD is the most common form of dementia and is characterized 
by a rapid progression from episodic memory deficits to a decline 
Table 1. Examples of histopathological findings in AD specimens in comparison with findings pertaining to another gray matter  
disease
a
 
Disease Histopathology Proteins(s)
b
 
Alzheimer’s (AD) Diffuse plaques; neuritic plaques; neurofibrillary tangles; 
amyloid angiopathy; Hirano bodies (with actin); vacuoles 
with argyrophilic granule 
APP; A; tau; presenilin 1; presenilin 2; apolipoprotein E; 2-
macroglobulin; caveolin; complement regulators; ubiquitin; Hsp 
Pick’s (PD) Pick cells with Pick bodies  A; tau 
aSource: Ref. [7]. See also ref. [13]. 
bProteins (and genes) normal or abnormal, known or suspected to play a role in pathogenesis. Abbreviations are: APP, amyloid precursor protein; A, amyloid beta. 
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in overall cognitive functions, impairing the patients’ ability to 
carry out activities of daily living with death occurring usually 
within 10 years after diagnosis [3]. In 2005, AD International con-
vened a multi-national panel of dementia experts to work on an 
evidence-based consensus on dementia prevalence worldwide. The 
panel estimated that there were 24.3 million people with dementia 
in the world in 2001, and predicted that this would rise to 42.3 mil-
lion in 2020, and to 81.1 million by 2040 [32]. 
 From a pathological point of view, AD is characterized by the 
cortical presence of extracellular deposits of amyloid- (A, 
Abeta), called senile or neuritic plaques, and intraneuronal inclu-
sions, called neurofibrillary tangles (NFTs) formed by accumula-
tion of abnormal filaments of tau, both found predominately in the 
brain regions involved in memory and learning [13, 18-23]. 
 There are currently several research efforts aimed at delaying 
the onset of AD and the potential cytoprotective effects of the heat 
shock response are an attractive target for pharmacological thera-
pies [27]. This is particularly relevant for neurodegenerative dis-
eases associated with protein misfolding and subsequent aggrega-
tion such as AD [13, 33, 34]. Molecular chaperones, many of which 
are Hsp as mentioned earlier, are the main components of the chap-
eroning system and play a variety of roles in addition to maintain-
ing protein homeostasis. Hsps can be overexpressed as a means for 
protection against stressors such as heat, oxidative stress, and 
ischemia. Hsp-chaperones mediate the refolding or degradation of 
stress-damaged proteins, depending on whether the damage is re-
versible or not and, thus, protect the cells from potential deleterious 
effects of unfolded-damaged proteins and promote the cell’s resis-
tance to, and recovery from, stress, all events pertinent to AD [33]. 
Besides, Hsps have many other functions inside and outside cells; 
for instance, they play roles in cell division, apoptosis inhibition, 
and metastasis of cancer cells [14]. 
 As mentioned earlier, many neurodegenerative diseases, includ-
ing AD, are characterized by the accumulation of aberrantly folded 
protein species [8-10], but it is not yet clear whether failure of the 
chaperoning system contributes to the pathogenic mechanism of 
AD. In other words, thus far there is no conclusive evidence that 
AD is a primary chaperonopathy although various observations 
indicate that this is a real possibility for at least some specific cases. 
 Chaperonopathies have been classified considering quantitative 
and qualitative features into by defect, by excess, and by mistake 
[35]. This classification is useful to establish a diagnosis with 
physiopathological implications and, thus, aids in decisions on 
treatment. Further, the classification is instrumental to conduct a 
differential diagnosis exercise that will lead to an accurate identifi-
cation of syndrome and disease, which is key to proper patient 
management.  
 Another way of classifying chaperonopathies that also helps the 
physician and, therefore, the patient, is based on whether they are 
inherited (genetic) or acquired [14]. The pathogenic chaperone may 
be normal or structurally altered and belong to any of the known 
Hsp-chaperones groups (Table 2). The structural alteration of a 
pathological chaperone may affect any of its functional domains or 
modules. When the chaperone is deficient, the aim is to replace it or 
to boost its functionality, and we can refer to this therapeutic mo-
dality as positive chaperonotherapy. If, on the contrary, the chaper-
one favors disease rather than protecting the cell and the organism, 
the therapeutic strategy aims at eliminating or blocking the patho-
logical chaperone. This latter therapeutic modality may be referred 
to as negative chaperonotherapy [25, 27]. 
 Involvement of chaperones in the pathogenesis of AD was first 
proposed following promoter analysis of the amyloid precursor 
protein (APP) gene, where a heat shock element (HSE) was found 
within its promoter [36]. As mentioned earlier, molecular chaper-
ones play essential roles in many cellular processes including pro-
Table 2. Subpopulations of Hsp-chaperones by molecular weight found to cause chaperonopathies
a
 
kDa Classical family Others causing chaperonopathies 
>200 None Sacsin 
100 - 199 Hsp100 - 110 VCP 
81 - 99 Hsp90 Paraplegin [SPG7]; UNC45B  
65 - 80 Hsp70/DnaK  Spastin [SPG4] 
55 - 64 Hsp60 (chaperonins Groups I 
and II, e.g., Cpn60 and CCT-
BBS 
BAG3; immunophilins FKB-type: peptidyl-prolyl cis-trans isomerases (PPI; FKBP5; FKBP10); 
myocilin; protein disulfide-isomerases (PDI; ER); SERPINH1 (Hsp47) 
35 - 54 Hsp40/DnaJ AIP; AIPL1; BCS1L; CALR; clusterin; DNAJC19; FOXRED1; melusin; morgana; SIL1; TBCE; 
torsin A 
<34 sHsp (crystallins) Alpha Hemoglobin-Stabilizing Protein (AHSP); alpha-synuclein; BCAP31; frataxin; Hsp10 
(Cpn10); HSPB11; immunophilin cyclophilin-type: peptidyl-prolyl cis-trans isomerase (PPI; 
PPIB); LRPAP1; RP2; SOD1-2 
aSource: Ref. [14]. 
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tein folding, translocation across membranes, refolding, and degra-
dation, and also in disaggregation of protein aggregates (see refer-
ences earlier). This explains why molecular chaperones are essen-
tial in the cellular defence against protein aggregation caused by 
misfolding both at intra- and extra-cellular levels and are potentially 
powerful suppressors of neurodegeneration. Moreover, chaperones 
regulate protein functions in order to protect against the oxidative 
stress accompanying the toxicity of amyloid aggregates and their 
expression is increased under conditions of amyloid challenge [37]. 
Also, a “sink hypothesis” has been proposed, positing that cellular 
toxicity and other manifestations of chaperone deficiency in AD, 
and other similar conditions, may develop because chaperones are 
being sequestered on the amyloid fibrils, as well as on the other 
protein precipitates and, thus, are re-directed away from their nor-
mal cellular tasks [38]. This situation can be described as a chaper-
onopathy by defect due to a quantitative deficit of chaperones at the 
time and place, i.e., where and when, they are needed [14]. Here, 
we discuss growing evidence suggesting a convergence between 
AD and molecular chaperones and the possibility that this disease 
may be a chaperonopathy. This approach provides a convenient 
point of view to examine AD and to look for new therapeutic ave-
nues. In this chapter, we focus on Hsp60, Hsp70, and Hsp90, dis-
cussing some of their biological, molecular, and pathological facets 
as they pertain to AD. 
2.1. Hsp60 
 Hsp60 is classically described as a mitochondrial protein whose 
gene is induced by various types of stressors as heat shock, oxida-
tive stress, and DNA damage [39]. Inside mitochondria, Hsp60 acts 
as a folding machine, together with Hsp10, for the correct folding 
of several mitochondrial proteins [40, 41]. Various studies, pub-
lished over the past several years, have demonstrated new sub-
cellular locations and functions for Hsp60, describing it as a ubiqui-
tous molecule with multiple roles in health and disease [42-44]. 
Moreover, detailed studies of the structure of Hsp60 have been 
reported that help understand the functions of this multifaceted 
molecule [45, 46]. 
 Hsp60 has both pro-survival and pro-death functions depending 
on tissue, cell type, and apoptosis inducers [47, 48]. It has been 
demonstrated that Hsp60 may associate with Bak or Bcl-XL in 
normal heart tissue, inhibiting their apoptotic potentials and conse-
quent cytochrome c release [49]. Hsp60 may influence tumor pro-
gression as suggested by its accumulation in the cytosol and plasma 
membrane of cancerous cells, reaching the extracellular space via 
secretory vesicles that in turn can modulate (induce, or inhibit?) 
anti-tumor immune responses [50-52]. Hyperacetylation of Hsp60 
in osteosarcoma cells is associated with the anticancer activity of 
geldanamycin and Hsp60 nitration is associated with the anti-tumor 
action of the histone deacetylase inhibitor SAHA [53, 54]. These 
findings support the idea that Hsp60 is a suitable target for antitu-
mor therapy and opens new prospects for novel drugs design [55], a 
concept that can be extended to the developing of agents to treat 
AD. 
 On the other hand, there exists published evidence supporting a 
cell death-promoting function for Hsp60. Mitochondrial Hsp60 
binds pro-caspase 3 in Jurkat and Hela cells, accelerating the matu-
ration of pro-caspase 3 by upstream activator caspases during apop-
tosis [56, 57]. 
 Hsp60 has also been implicated in the mechanism of cell aging 
[58]. Senescent cells in culture become flat and enlarged and can be 
maintained in a viable state for long periods, but cannot be induced 
to divide by mitogenic stimuli [59]. Senescence-induced resistance 
to apoptosis leads to an increase in the number of senescent cells 
inside tissues, with consequences on the feebleness of tissue integ-
rity and on neoplastic transformation, likely promoting the devel-
opment of late-life cancers [60]. During replicative senescence of 
normal human skin fibroblasts, the levels of Hsp60 increase and 
form a complex with MOK, a MAP kinase involved in signal trans-
duction to the nucleus [61]. Furthermore, a correlation between 
increased levels of Hsp60 and senescence of skin fibroblasts was 
shown to involve interaction between Hsp60 and mtHsp70 [62]. 
 Hsp60 may be involved in autoimmune processes: it may act as 
autoantigen because of the high sequence similarity (molecular 
mimicry) between human and foreign Hsp60 from bacteria and 
parasites that colonize humans, which leads to anti-Hsp60 antibody 
cross-reactivity [14, 63]. Hsp60 has high structural similarity also 
with human proteins such as myelin-associated protein, glutamic 
acid decarboxylase, and acetylcholine receptor, further suggesting 
that circulating Hsp60 may serve as autoantigen for the generation 
of an autoimmune response [14]. Consequently, Hsp60 may trigger 
autoimmune pathological conditions, including some affecting the 
nervous system such as multiple sclerosis and myasthenia gravis 
[14, 64]. 
 Extracellular Hsp60 can interact with a variety of receptors 
present on the plasma-cell membrane surface, such as CD14, CD40, 
CD91 and TLRs [65, 66]. Hsp60 influences the pro-inflammatory 
capacity of adipocytes binding an adipocyte receptor and contribut-
ing to obesity-associated inflammatory disease leading to diabetes 
[67]. The chaperonin has also been implicated in the pathogenesis 
of chronic inflammatory conditions such as Crohn’s disease [68], 
ulcerative colitis [69, 70], alcoholic liver disease [71], chronic ob-
structive pulmonary disease [72], and atherosclerosis [73]. 
 Neural expression of Hsp60 increases over the course of devel-
opment, a trend consistent with the changes of mitochondrial con-
tent in the brain [74]. In brain, Hsp60 is endogenously expressed in 
astrocytes, neurons, microglia, oligodendrocytes, and ependymal 
cells [74]. This distribution suggests an active participation of this 
chaperonin in many functions of the brain, both in normal and 
pathological conditions. Hsp60 exposed on the surface of astrocytes 
and neuroblastoma cells interacts with TREM2, a receptor that, if 
mutated, is responsible for genetic disorders affecting bones and 
brain [75]. Extracellular Hsp60, through binding to LOX-1 (lectin-
like oxidized low-density lipoprotein receptor-1), may promote 
microglia-mediated neuroinflammation and a prolonged delay in 
the induction of Hsp60 in injured regions of the brain [76, 77]. For 
example, expression of Hsp60 has been found increased in the 
brainstem after subarachnoidal haemorrhage, forebrain or focal 
cerebral ischemia, and neonatal hypoxia-ischemia [77]. Increased 
levels of the chaperonin have also been found in both animals and 
patients with temporal lobe epilepsy in response to epileptic sei-
zures [78]. 
 Given that Hsp60 plays a critical role in assisting the correct 
folding of other mitochondrial proteins and enzymes, a deficiency 
in its concentration and/or function together with the increased 
vulnerability to oxidative stress observed in the tissues of neurode-
generative disorders, may lead to severe conditions caused by pro-
tein misfolding and aggregation [24, 79]. This would be an Hsp60 
chaperonopathy. 
 Post-translational modifications (phosphorylation, acetylation, 
Y-nitration, S-nitrosylation, methylation, oxidation, and ubiquitina-
tion) of Hsp60 may occur through a variety of mechanisms, result-
ing in the loss or impairment of its functions [54, 80]. Such Hsp60 
deficiency might be a common cause of mitochondrial dysfunction, 
which would be significant since AD has been described as a disor-
der aggravated by oxidative stress and/or mitochondrial defect 
characterized by protein conformation abnormalities (Fig. 1) [29, 
30, 77, 81]. 
 Hsp60 was found to be involved in preventing aggregation by 
trapping misfolded forms of prion protein scrapie ant thus prevent-
ing glycation, which is known to contribute to the pathogenesis of 
protein deposition [82]. Expression of Hsp60 is significantly de-
creased in the parietal cortex of AD subjects and in the cerebella of  
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Fig. (1). Stress and Hsp60 in Alzheimer’s disease: possible pathogenic 
pathways. Oxidative stress (and other types of stress) may cause Hsp60 
alterations, e.g., post-translational modifications, resulting in an impairment 
or loss of the chaperonin’s functions with various consequences (some of 
which are indicated in the figure) and, thus, contributing to the development 
and/or progression of Alzheimer’s disease. UPR, unfolded protein response. 
 
a rat model of AD, suggesting a defect in the protective role of this 
chaperonin in the AD brain [81, 83]. In support of the neuroprotec-
tive effects of Hsp60, it has been demonstrated that in a human 
neuroblastoma cell line, induced expression of the chaperonin pre-
vented intracellular -amyloid-induced inhibition of complex IV 
and consequently reduced apoptosis [84]. A25–35 induced oxida-
tion of Hsp60 in fibroblasts derived from AD patients [85] and, 
also, Hsp60 was oxidized by A1–42 leading to a loss of function 
of the chaperonin, which caused an increase in protein misfolding 
and aggregation [86]. Again, this would be a chaperonopathy by 
defect. 
 Hsp60 levels were found elevated in lymphocytes from AD 
patients when compared to controls [87] and sporadic AD subjects 
exhibited a significant (~40-60%) increase in expression levels of 
genes activated by the mitochondrial unfolded protein response 
(mtUPR), including genes encoding mitochondrial chaperones such 
as Hsp60 and others [30]. 
 Administration of an A amyloid-Hsp60 peptide-conjugate 
vaccine led to the induction of anti-A-specific antibodies, associ-
ated with a significant reduction of cerebral amyloid burden and of 
the accompanying inflammatory response in the brain of a mouse 
model of AD [88]. On the contrary, other authors have attributed a 
deleterious effect to the elevated expression of Hsp60 in AD. For 
example, it was shown that Hsp60 mediates in vitro the transloca-
tion of APP to the mitochondria leading to dysfunction of this or-
ganelle [89]. 
 All the findings discussed in the preceding paragraphs indicate 
that more research is needed to determine with certainty if AD is an 
Hsp60 chaperonopathy by defect, or by excess, or by mistake. 
However, the data do show that this chaperonin is implicated in the 
disease and deserves more research to clarify what it does, when, 
and how, as a fundamental preliminary step to the developing of 
specific Hsp60 chaperonotherapy, positive or negative, as the case 
might be. 
2.2. Hsp70 
 The Hsp70 family is large with at least 17 members [90], some 
of which are stress-inducible (e.g., HSPA1A also named Hsp70i), 
while others are constitutively expressed (e.g., HSPA8 also called 
Hsc70). The stress-inducible Hsp70 proteins are among the first to 
be upregulated upon heat shock to cope with the protein damage-
misfolding caused by stress. Hsp70 chaperones are found in most 
cellular compartments, including the nucleus and cytoplasm 
(Hsc70), mitochondria (mtHsp70, also named HSPA9 and mor-
talin), and ER (Grp78, also known as BiP) [90, 91]. 
 Hsc70 assists the folding of client proteins via an ATP-
dependent mechanism binding to short extended hydrophobic re-
gions of the misfolded client proteins and, thereby, prevents aggre-
gation of the unfolded clients [92]. By differentially associating 
with the co-chaperones Hsp40, and with Hsp90, Hsp70 achieves 
versatility of function in the various cellular compartments [93]. 
 Hsp70 inhibits apoptosis acting on the caspase-dependent 
pathway at several steps both upstream and downstream of caspase 
activation and, also, on the caspase-independent pathway. A study 
of the correlation between the anti-apoptotic effects of Hsp70 and 
inhibition of caspase activity suggested that the point of Hsp70 
intervention was upstream of caspase-3 activation. Subsequently, it 
was demonstrated that Hsp70 is able to directly inhibit caspase 
processing by interacting with Apaf-1 and prevent the recruitment 
of procaspase-9 to the apoptosome [94]. Overproduction of Hsp70 
leads to increased resistance against apoptosis-inducing agents such 
as tumor necrosis factor-a (TNFa), staurosporin, and doxorubicin, 
while downregulation of Hsp70 levels by siRNA leads to increased 
sensitivity towards these agents [95-97]. In various kinds of tumors 
increased Hsp70 levels are observed that correlate with increased 
malignancy and resistance to therapy [98]. For example, Hsp70 
binds tumor-suppressor proteins, such as p53 and HER2, and thus 
allows unlimited cellular growth and increased resistance to chemo-
therapy in breast cancer, consequently, elevated levels of Hsp70 are 
associated with poor prognosis in breast and endometrial cancers 
[98]. Downregulation of the Hsp70 levels in some types of cancers 
induce differentiation and cell death [99]. 
 Hsp70 has the ability to trigger the activation of the immune 
response by stimulating both innate and adaptive immunities. The 
immunogenicity of Hsp70 and its capacity to activate antigen-
specific immunity have made this protein a promising candidate for 
vaccine development. With respect to innate immunity, Hsp70 is 
secreted from host cells into the extracellular milieu, and this ex-
tracellular Hsp70 triggers innate immunity via activation of antigen 
presenting cells (APCs) [100]. Regarding adaptive immunity, 
Hsp70 is an abundant antigen for both B and T cells. For example, 
the P. falciparum Hsp70 is expressed by most parasites during their 
life cycles and it is recognized by serum antibodies from malaria 
patients [101]. 
 The numerous roles of the various Hsp70 proteins relate not 
only to oncogenesis and the immune response, as discussed above, 
but also to other pathological processes, such as neurodegeneration 
and senescence. Neurodegenerative diseases such as AD, Parkin-
son’s disease, Huntington’s chorea, and spinocerebellar ataxias are 
characterized by excessive apoptosis. In some model systems, over-
expression of Hsp70, or one of its co-chaperones, was shown to 
overcome the neurodegenerative symptoms induced by expression 
of a disease-related gene [102, 103]. 
 Senescence in cell culture as well as aging in vivo is correlated 
with a continuous decline in the ability to mount a stress response 
[104]. Age-related symptoms and diseases reflect this decreased 
ability to cope with cellular stresses. Interestingly, centenarians 
seem to be an exception to the rule, as they show a significant in-
duction of Hsp70 production after heat shock challenge [105]. In 
the brains of patients affected by AD, an increased level in the ex-
pression of Hsp70 has been reported [106], suggesting a potential 
role of Hsp70 in the pathogenesis of this disease. APP interacts 
with the ER resident chaperone BiP/Grp78 during its normal proc-
essing in the ER-Golgi pathway, suggesting that an increase of 
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Grp78 levels may help proper processing of APP therefore reduce 
amyloid production [107].  
 Immunohistochemical studies and expression analyses in AD 
brain tissue showed that expression levels of Hsp70 were elevated 
in affected regions, and this elevation appeared to be correlated to 
the presence of activated glia and dysregulated or stressed neurons 
[33]. The increase in Hsp70 levels could be related to an increase in 
the expression of the transforming growth factor  1 (TGF-1), an 
enzyme that is thought to be responsible for the degradation of A 
[108]. In addition, cytosolic Hsp70 was shown to inhibit early 
stages of amyloid aggregation protecting against intracellular A 
[109]. It was reported that chaperone proteins, including Hsp70, can 
recognise abnormal tau and reduce its concentration by facilitating 
its degradation and de-phosphorylation [110-112]. Moreover, it has 
been demonstrated that tau binds directly to Hsp70, and Bag-1 has a 
role in this interaction [113]. Therapeutics that exploit the ability of 
Hsp70 to selectively target abnormal tau can rapidly and potently 
rescue the synaptic dysfunction that occurs in AD and other 
tauopathies [114]. 
 It is clear from the above paragraphs that various members of 
the Hsp70 family are implicated in AD and it is also apparent that, 
as the pathogenic and/or protective mechanisms in which these 
chaperones (with or without their co-chaperones) participate are 
being elucidated, new perspectives for Hsp70 chaperonotherapy 
will be unveiled. 
2.3. Hsp90 
 Hsp90, of which in humans there are at least five varieties 
(HSP90A in cytosol; HSP90alpha, HSP90beta, HSP90B (or Grp94) 
in the ER, and TRAP in mitochondria [14] is the most abundant 
protein in eukaryotic cells under unstressed conditions, and like 
other molecular chaperones, is present in one form or another in 
most cellular compartments such as the cytosol, endoplasmic reticu-
lum, mitochondria, and chloroplast [115]. Hsp90 is indispensable 
for cell survival, playing an important role in the folding of many 
proteins pertaining to essential signalling pathways, and in the re-
folding of denatured proteins after stress [115, 116]. Hsp90 is an 
ATP-dependent chaperone, with a unique N-terminal ATP binding 
site (in addition to another C-terminal nucleotide binding site) that 
has allowed for the development of specific Hsp90 inhibitors such 
as geldanamycin, a macrocyclic antitumor agent and its less toxic 
analog 17-allylamino-17-demethoxygeldanamycin (17AAG) [115]. 
Hsp90 does not bind to non-native proteins but rather to substrates 
in their native states and targets a specific set of client proteins that 
are involved in signal transduction [117]. 
 Hsp90 has been shown to interact with important client kinases, 
including ErbB2, Src, Abl, and Met tyrosine kinases, and cyclin-
dependent serine kinases [116], which are part of an intricate multi-
dimensional signalling web that integrates information from various 
origins. Many of these client proteins are known to be bound to 
Hsp90 in an inactive state and are activated upon dissociation from 
Hsp90. For example, the catalytic domain of raf proteins, members 
of MAP kinase kinase kinases (MEKKs), are in a heterocomplex 
with Hsp90, and are activated upon dissociation from this Hsp90 
such as in stress conditions [107]. Moreover, the abundant cytosolic 
Hsp90 under normal conditions has the capacity to bind to and keep 
stress transcription factors such as Heat Shock Factor-1 (HSF-1) in 
a monomeric inert state. Upon heat shock, HSF-1 is released from 
the Hsp90 complex due to the increased demand for chaperones by 
proteins in need of assistance for folding and refolding. This repre-
sents the first step in the activation of HSF-1 and the inducible 
Hsp90 offers a negative feedback loop to control the transcriptional 
activity of HSF-1 [107]. 
 Hsp90 is overexpressed in cancer cells and is essential for the 
malignant transformation and progression of several tumor types 
such as bladder, breast and lung cancers, and leukemia [98, 118]; 
these being examples of chaperonopathies by mistake. Conse-
quently, blockage of Hsp90 function in these cancers via inhibitory 
compounds may be a valuable therapeutic strategy [119], and by 
extension the same principles may be applied to the developing of 
compounds to treat AD if it is demonstrated that Hsp90 favors dis-
ease (AD would thus be an Hsp90 chaperonopathy by mistake). 
 Some observations suggest an additional role for Hsp90 in 
buffering some of the client proteins that might be directly respon-
sible for disease progression [120, 121]. Hsp90 was shown to in-
hibit early stages of amyloid aggregation [109] and administration 
of Hsp90 inhibitors to primary neurons prevented A-induced neu-
rotoxicity [122]. The complex of Hsp90 and Hsp70/Hsp40 also can 
inhibit A formation and slow down the rate of aggregation in a 
chaperone concentration-dependent manner (Fig. 2) [123]. Hsp90 
outside the cells may facilitate A clearance by the activation of 
microglial phagocytosis and A degradation by NF-B and p38 
MAPK activation through the Toll-like receptor-4 (TLR4) pathway 
[109, 124]. All these observations suggest that positive chaperono-
therapy centred on Hsp90 could be a promising means to treat AD. 
 The other hallmark of the pathology of AD is the accumulation 
of tau, which leads to the formation of toxic NFTs. Chaperones are 
necessary to maintain tau in a non-aggregated state. Positive corre-
lations have been found in the soluble protein levels from AD brain 
tissue between tau and molecular chaperones including Hsp90 
[125]. Hsp70 and Hsp90 work together to coordinate tau homeosta-
sis [126]. Pharmacologic inhibition of Hsp90 significantly reduced 
intracellular levels of the disease-associated phosphorylated tau 
species pS202/T205 and pS396/S404 (Fig. 2) [33]. These Hsp90 
inhibitors primarily facilitate the clearance of phosphorylated tau 
via proteasomal degradation [33]. Mutant tau is maintained in 
tauopathies by Hsp90 and the inhibition of Hsp90 leads to reduction 
in the pathogenicity of these mutant species [121]. These data sug-
gest that negative chaperonotherapy aimed at Hsp90 inhibition 
might offer hopes for developing efficacious treatment for AD. 
 Important regulators of the Hsp90 machinery are co-chaperones 
and posttranslational modifications, e.g., acetylation, nitrosylation, 
and phosphorylation, of the Hsp90 protein itself [115]. For instance, 
the acetylation of Hsp90 inhibits client binding thereby enhancing 
the proteasomal degradation of the unbound clients. Tau is a client 
for Hsp90 complexes. If tau is in an abnormal or modified form, 
then it can trigger the recruitment of CHIP, a cochaperone of 
Hsp90, to the complex, which induces the ubiquitination of tau and 
activates its downstream degradation steps [123]. 
 Hsp90 inhibition may be suitable to a dual therapeutic approach 
in AD (Fig. 2). On the one hand, Hsp90 inhibitors may counteract 
tau protein hyper-phosphorylation and subsequent aggregation. On 
the other hand, Hsp90 inhibitors may reduce the protective stress 
response. Hsp90 can tightly bind and thus down-regulate the activ-
ity of HSF-1 but in the presence of cellular stress (a common event 
in AD), HSF-1 dissociates from Hsp90, translocates to the nucleus 
and binds heat-shock response elements, thereby inducing heat 
shock response genes, such as those encoding the proteins Hsp27, 
Hsp40, Hsp70, and Hsp90. The expression of these chaperone 
genes expands the buffering capacity of the cell and restores protein 
homeostasis under stressful conditions [127].  
 Another aspect to take into account in this context is that cell 
life and functions depend on many extracellular signals and that 
these signals, in turn, depend on carriers that travel communicating 
different cells. In the last years, growing evidence supports the 
pivotal role of the extracellular vesicles (EVs), such as exosomes, 
in cell-cell communication. The roles of exosomes in mediating the 
pathogenesis of AD were initially attributed to the capacity of these 
nanovesicles to serve as vehicles for the transport of the A pep-
tides to the extracellular environment [128]. Recently, it has been 
demonstrated that Hsp70 and 90 intercellular transport via 
exosomes contributes to maintenance of protein homeostasis at the 
organismal level [129]. The data indicate that EVs are promising 
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elements for directing specific therapeutic agents to selected cells in 
which the chaperoning system needs re-enforcements or repair. 
 Since neurons are a terminally differentiated, i.e., they are a 
post-mitotic cell type, it has been suggested that neurons are espe-
cially susceptible to the cumulative effects of misfolded proteins as 
they are unable to reduce the load of toxic intermediates through 
consecutive rounds of mitosis [37]. Therefore, the capacity of neu-
ronal chaperones to reduce misfolded proteins is essential for main-
taining neuronal integrity. This again clearly points to positive 
chaperonotherapy as one promising treatment modality for AD. 
CONCLUSION AND PERSPECTIVES 
 From the data discussed in the preceding three sections, we can 
say for Hsp60, Hsp70, and Hsp90 that there are clear indications of 
their active participation in the cellular and tissue phenomena typi-
cal of AD, but the pertinent molecular mechanisms are still not 
fully understood. Nevertheless, there is growing evidence suggest-
ing that the development of pathological features in AD could be 
the result of chaperone malfunctioning by excess, defect, or mis-
take. Consequently, AD is a candidate for chaperonotherapy in its 
various forms, positive, negative, and combined. These possibilities 
are currently under intense scrutiny in our laboratories and in those 
of many others, ensuring a bright future for research on this serious 
and widespread neurodegenerative condition and nurturing hope for 
those affected by it. 
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